Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Current Deferred Revenue: 2014-2024

Historic Current Deferred Revenue for AC Immune (ACIU) over the last 11 years, with Dec 2024 value amounting to $97.1 million.

  • AC Immune's Current Deferred Revenue rose 62409240.74% to $97.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $97.1 million, marking a year-over-year increase of 62409240.74%. This contributed to the annual value of $97.1 million for FY2024, which is 62409240.74% up from last year.
  • AC Immune's Current Deferred Revenue amounted to $97.1 million in FY2024, which was up 62,409,240.74% from $155.57 recorded in FY2023.
  • In the past 5 years, AC Immune's Current Deferred Revenue registered a high of $97.1 million during FY2024, and its lowest value of $155.57 during FY2023.
  • In the last 3 years, AC Immune's Current Deferred Revenue had a median value of $609,319 in 2022 and averaged $32.6 million.
  • As far as peak fluctuations go, AC Immune's Current Deferred Revenue tumbled by 99.97% in 2023, and later spiked by 62,409,240.74% in 2024.
  • AC Immune's Current Deferred Revenue (Yearly) stood at $338,484 in 2020, then skyrocketed by 131.81% to $784,648 in 2021, then fell by 22.34% to $609,319 in 2022, then tumbled by 99.97% to $155.57 in 2023, then spiked by 62,409,240.74% to $97.1 million in 2024.